Grant Skrepnek to Drug Therapy, Combination
This is a "connection" page, showing publications Grant Skrepnek has written about Drug Therapy, Combination.
Connection Strength
0.205
-
Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid. J Manag Care Spec Pharm. 2018 Jul; 24(7):664-676.
Score: 0.146
-
Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm. 2013 Jan-Feb; 19(1 Suppl A):S41-53.
Score: 0.025
-
Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma. Curr Med Res Opin. 2008 Mar; 24(3):859-67.
Score: 0.018
-
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Pharmacotherapy. 2007 Jun; 27(6):813-24.
Score: 0.017